ARTICLE | Clinical News
Acclaim: Phase II
December 15, 2003 8:00 AM UTC
Angiogenix began a double-blind, placebo-controlled, international Phase II trial in 170 patients with coronary artery disease who suffer from chronic, stable, effort-induced angina. The primary endpo...